These observations make it imperative that a diagnosis of CD be definitively made, that consideration be given to screening tools and the populations to whom they should be applied, and that parameters are carefully defined to correctly interpret the results of the screen. Currently there are at least 3 guidelines, 2 written for children and 1 for adults, on how to evaluate for and treat CD. [5] [6] [7] These guidelines recommend screening based on family history, health status, and symptoms and rely on the immunoglobulin A (IgA) antibody for transglutaminase (tTG). For IgA-deficient people, the immunoglobulin G tTG is often used. All of the guidelines focus on symptoms as the factor used to initiate screening for CD, unless a first-degree relative has CD or the patient suffers with one of the diseases closely associated with CD, such as type 1 diabetes or Down syndrome, among others.
The large and carefully designed study by Rosen et al in this issue 8 calls into question the validity of using symptoms to identify children for screening. The authors invited 10 041 children and their parents to participate in a population-based CD screening of 12-year-olds. Children known to have CD were excluded. Before learning their CD marker results, children completed a questionnaire on symptoms in their classrooms, supervised by a teacher or nurse. Parents reported on the child' s CD-associated conditions. Serology was then obtained. Children underwent a small-bowel biopsy if their tTG-IgA or tTGimmunoglobulin levels were elevated. Surprisingly, the authors found there was no correlation between the presence of symptoms and the diagnosis of CD; symptoms did not discriminate unrecognized CD children from their non-CD peers. In addition, there was no difference in CD prevalence between those with and without CD-associated conditions. These results call into question the recommendations of the guidelines. Importantly, they raise concern for the guideline that recommends a gluten-free diet be initiated without a biopsy when "signs or symptoms suggestive of CD and high anti-TG2 titers with levels .10 times ULN" are present. Accepted for publication Nov 7, 2013 Knowing how important it is to diagnose CD for longevity and health, the Although not addressed in this study, the lack of correlation of symptoms with the diagnosis of CD raises questions about the diagnosis of nonceliac gluten "sensitivity" (NCGS). The diagnosis of this entity rests solely on symptoms and the response to a trial of a gluten-free diet. With Rosen' s observations, can we rely on symptoms to make a diagnosis? Can there be another way to diagnose NCGS? Or is NCGS related to other factors 9 and the response to the withdrawal of gluten simply a highly effective placebo? 10 Before initiating a gluten-free diet in these children, CD must be excluded.
This carefully designed and executed study raises important questions, suggests recommendations for screening of CD be revisited, and further suggests that care be taken in prescribing a gluten-free diet when a diagnosis of CD has not been made. 
